- Home
- RRGB vs ZURA Comparison
RRGB vs ZURA Comparison
Compare RRGB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRGB
- ZURA
- Stock Information
- Founded
- RRGB 1969
- ZURA 2022
- Country
- RRGB United States
- ZURA United States
- Employees
- RRGB N/A
- ZURA N/A
- Industry
- RRGB Restaurants
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RRGB Consumer Discretionary
- ZURA Health Care
- Exchange
- RRGB Nasdaq
- ZURA Nasdaq
- Market Cap
- RRGB 91.6M
- ZURA 76.6M
- IPO Year
- RRGB 2002
- ZURA N/A
- Fundamental
- Price
- RRGB $2.78
- ZURA $1.21
- Analyst Decision
- RRGB Strong Buy
- ZURA Buy
- Analyst Count
- RRGB 4
- ZURA 7
- Target Price
- RRGB $11.88
- ZURA $14.33
- AVG Volume (30 Days)
- RRGB 294.7K
- ZURA 326.3K
- Earning Date
- RRGB 05-28-2025
- ZURA 05-08-2025
- Dividend Yield
- RRGB N/A
- ZURA N/A
- EPS Growth
- RRGB N/A
- ZURA N/A
- EPS
- RRGB N/A
- ZURA N/A
- Revenue
- RRGB $1,248,560,000.00
- ZURA N/A
- Revenue This Year
- RRGB $0.60
- ZURA N/A
- Revenue Next Year
- RRGB N/A
- ZURA N/A
- P/E Ratio
- RRGB N/A
- ZURA N/A
- Revenue Growth
- RRGB N/A
- ZURA N/A
- 52 Week Low
- RRGB $2.50
- ZURA $0.97
- 52 Week High
- RRGB $9.20
- ZURA $6.35
- Technical
- Relative Strength Index (RSI)
- RRGB 40.04
- ZURA 43.46
- Support Level
- RRGB $2.55
- ZURA $1.17
- Resistance Level
- RRGB $3.02
- ZURA $1.55
- Average True Range (ATR)
- RRGB 0.19
- ZURA 0.14
- MACD
- RRGB 0.06
- ZURA -0.02
- Stochastic Oscillator
- RRGB 53.85
- ZURA 7.83
About RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. Its brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.